Criterium, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.criteriuminc.com
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05458674
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Swedish Cancer Institute, Issaquah, Washington, United States
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Criterium, Inc.
- Registration Number
- NCT05180422
- Locations
- 🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04791384
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04739358
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04567420
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04169347
- Locations
- 🇺🇸
Kansas University Cancer Center, Westwood, Kansas, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02706626
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Vanderbilt Unversity Medical Center, Nashville, Tennessee, United States
🇺🇸University of Texas, Southwestern, Dallas, Texas, United States
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02638909
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01789242
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States